New Three-Drug Therapy Doubles Survival Time for Advanced Breast Cancer Patients

The therapy, combining inavolisib, palbociclib, and fulvestrant, significantly delays disease progression and is hailed as a transformative breakthrough.

The INAVO120 study involved 325 patients across 28 countries, focusing on those with PIK3CA-mutated HR+ HER2- breast cancer.
Patients receiving the three-drug combination experienced an average of 15 months without disease progression, compared to 7.3 months for the placebo group.
The therapy includes inavolisib, a new drug that blocks PI3K protein activity, alongside palbociclib and fulvestrant.
While the treatment is not yet approved in the UK, it received FDA approval in the US earlier this month.
Researchers emphasize the treatment's potential to prevent cancer resistance, offering longer-term responses and improved quality of life.